A European Multicenter Study of 616 Patients Receiving the Freedom Solo Stentless Bioprosthesis

• Type: Article in International Scientific Journal
• Date: 2016

Authors

Thalmann, M (Author) Other; Grubitzsch, H (Author) Other; Matschke, K (Author) Other; Glauber, M (Author) Other; Tan, E (Author) Other; Francois, K (Author) Other; Amorim MJ (Author) FMUP; Hensens, AG (Author) Other; Cesari, F (Author) Other; Feyrer, R (Author) Other; Diegeler, A (Author) Other; Veit, F (Author) Other; Repossini, A (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: ANNALS OF THORACIC SURGERY

Vol. 101

Pages: 100-109

ISSN: 0003-4975

Indexing

ISI Web of Knowledge - 7 Citations

Other information

Authenticus ID: P-00K-08R

DOI: 10.1016/j.athoracsur.2015.06.096

Abstract (EN): Background. The purpose of this study was to evaluate the safety and performance of the Freedom Solo valve in aortic valve replacement by clinical and hemodynamic outcomes. Methods. Six hundred sixteen patients underwent aortic valve replacement in 18 European centers; mean age was 74.5 +/- 5.9 years, 54.1% of the patients were male, and concomitant procedures were performed in 43.2% of the patients. The majority (69%) of the implanted sizes were 23 mm and 25 mm. Results. At 1 year, overall survival was 94.0%, whereas freedom from valve-related death was 98.6%. There were 9 (1.5%) early (<= 30 days) and 27 (4.4%) late (>30 days) deaths. Early and late valve-related mortality was 0.3% (n = 2) and 1.1% (n = 7), respectively. Freedom from explant was 97.6%; 10 valves were explanted for endocarditis and 4 for paravalvular leak. There were 10 (1.6%) early and 5 (0.8%) late strokes. Atrioventricular block requiring pacemaker implant occurred in 8 (1.3%) and 1 (0.2%) patients in the early and late postoperative period, respectively. Thrombocytopenia was seen in 27 cases (4.4%) in the early postoperative period. Preoperatively, 93.8% of patients were in New York Heart Association functional classes II through IV, whereas at 1 year 96.9% of patients were in New York Heart Association functional classes I and II. At 1-year follow-up, mean and peak pressure gradients were 7.2 and 14.6 mm Hg, respectively. Indexed left ventricular mass decreased by 12% from 138 g/m(2) at discharge to 122 g/m(2) at 1 year. Conclusions. At 1-year follow-up after Freedom Solo implantation, we found acceptable clinical results with low mortality and morbidity and good hemodynamic performance, confirming safety and effectiveness in this multicenter experience. (C) 2016 by The Society of Thoracic Surgeons

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10